This week, which stocks lagged or dragged? Weekly Winners column keeps up with market trends, helping Tigers sort out the week's hottest sectors, stock winners and important news.
Below are the top 10 US stock gainers for the week ended Jan. 17:
Johnson & Johnson agreed to acquire mental-illness drug developer Intra-Cellular Therapies for about $15 billion, evidence of the pharmaceutical industry's renewed interest in neuroscience bets with vast but unrealized promise.
The deal would add to J & J's portfolio lumateperone, an Intra-Cellular drug branded Caplyta, a pill that treats bipolar depression and schizophrenia. Analysts predict the drug's sales could reach $4 billion a year by 2030 if regulators approve expanding its use to include major depressive disorder.
Bitcoin rejoined the crypto rally on Friday amid reports that President-elect Donald Trump could soon release an executive order making crypto a national priority.
The price of the flagship cryptocurrency rose to $105,320, according to Coin Metrics.
Shares of MicroStrategy rose 21% this week.
A short seller and research firm, Hindenburg Research, which specializes in forensic financial research, announced Wednesday that it was closing its doors.
The most recent report filed by the company was on Jan. 2 about auto retailer Carvana Co., which it called a “father-son accounting grift for the ages.” In a statement, Carvana called the firm’s report “intentionally misleading and inaccurate.” The stock fell more than 11% the day after Hindenburg published its report but has since recovered.
Chinese e-commerce platform operator JD.com on Friday introduced a gifting feature on its mobile app, joining rival Alibaba Group Holding in countering the competitive pressure from social media giant Tencent Holdings, which launched a similar feature last month.
When browsing a selection of eligible merchandise, JD.com app users will see a button labelled “Gifting IT.” After clicking it, users follow a few simple steps to pay for an item and have it shipped directly to the recipient.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。